二重盲検法によるFosfomycin(FOM)とCarbenicillin indanyl(I-CBPC)の複雑性尿路感染症に対する薬効比較

Abstract

Comparative double blind trial of fosfomycin calcium (FOM) and carbenicillin indanyl sodium (I-CBPC) was performed in 72 patients of complicated urinary tract infection with Pseudomonas or Proteus species. Patients were treated orally for a week at a daily dose of 2 g of FOM or I-CBPC. The results obtained were summarized as follows: 1. The background characteristics of two groups were statistically analyzed, and they were to be satisfied in their uniformity as the subject of this trial. 2. The degree of improvement of symptoms and urinary findings, and the change of bacterial count and species in urine were also compared and were not significantly different between the two groups. 3. The clinical effects were excellent in 4 cases, good in 7 cases, fair in 15 cases, and poor in 11 cases out of 37 cases of the FOM group, and excellent in 4 cases, good in 12 cases, fair in 11 cases, and poor in 8 cases out of 35 cases of the I-CBPC group. No significant difference was obtained between the two groups. 4. The incidence of adverse reactions was 2 out of 41 cases of the FOM group (4.9%) and lout of 43 cases of the I-CBPC group (2.3%), showing no significant difference. Considering the data described above, there was no significant difference between FOM and 1-CBPC groups on overall clinical efficacy, utility, improvement of symptoms and findings, and incidence of adverse reactions.